醫藥品的投資組合經營管理 是由出版商Cutting Edge Information在2011年12月所出版的。
這份英文市場調查報告書包含97 Pages 價格從美金7695起跳。
對生命科學企業來說，擴大核心資產成了從未有過的重要。投資組合這個策略性計畫絕不可欠的構成要素，甚至可以影響左右企業未來的決策。藉由適當的化合物開發，都可能蘊藏著數十億美金的長期性收益的可能性。
本報告以醫藥品企業·生化科技企業為對象進行調查的結果，彙整投資組合&生命週期經營管理的基準分析與最佳業務實踐，為您概述為以下內容。
摘要整理
投資組合經營管理:小組結構·資源·關注的區域
- 投資組合經營管理的群組結構
- 投資組合經營管理的資源
- 投資組合經營管理隊的效能等級
- 投資組合經營管理隊的焦點
投資組合經營管理策略
生命週期經營管理:投資組合收益的最大化
Abstract
Overview
Prioritize, Support and Protect Assets
Among life science companies, the drive to maximize core assets has never been
more critical. An integral part of strategic planning, the portfolio
management process influences decisions that directly impact company fortunes
- especially when advancing the right compounds creates the potential for
billions of dollars in long-term revenue.
Effective portfolio management requires foresight and preparation, a challenge
given the daily pressures faced by all organizations. Top-performing companies
review, update and execute their portfolio strategies on a consistent basis.
For many organizations, however, numerous obstacles make it difficult to take
an ideal approach to portfolio management.
This study is your roadmap to optimizing portfolio management strategy.
Designed to improve companies' ability to progress compounds from the
pre-clinical stage to commercial brand management, it showcases benchmarks and
best practices for teams managing both clinical projects and marketed brands:
Build a portfolio management team
Every company must assess and prioritize its assets, whether a formal group
oversees the process or not. Explore different approaches to team structure,
examine budgets and headcount benchmarks, and track decision-making processes.
Reinforce your portfolio management strategy
Follow a step-by-step guide to improving strategy, learning the criteria
necessary to advance some projects while pruning others. Understand business
development's role in portfolio analysis, and accurately weight the key
factors that influence long-term success.
Boost revenues and extend market exclusivity
Portfolio management stretches from discovery to patent expiration, so it's
important to ensure smooth transitions from clinical portfolio planning to
branded lifecycle management. Analyze ROI and time investments to deploy a
diverse array of LCM tactics that extend brand success.
Companies
Companies Included in Portfolio Management Research
Pharmaceutical and biotech companies of all sizes were included in this
research to capture the strategies and practices of organizations facing
different types of portfolio and lifecycle management challenges.
- Top-performing strategies: dollars earned per $1 spent
- Prominence of dedicated lifecycle management teams
- Department to which lifecycle management teams report
- Groups that perform financial calculations and select LCM tactics for
launched compounds
- Final decision maker on lifecycle management tactics for launched compounds
- Average percentage of US and EU revenues lost in first year of generic
competition
- Significance of generics threats to LCM teams
- Average time spent implementing LCM strategy
- Additional dollars earned per dollar spent on new indications, new
formulations, and next-generation products
- Additional dollars earned per dollar spent on combination products,
pediatric exclusivity, authorized generics, and disease management programs
- Percentage of companies using litigation, citizen petitions or pediatric
exclusivity
- When planning begins for pediatric exclusivity strategies, litigation
strategies, pricing strategies and counter-promotion strategies
Table of Contents
- 7 Executive Summary
- 11 Study Methodology
- 12 Managing a Compound's Lifecycle: Four Recommendations for Success
- 19 Portfolio Management Group Structure, Resources and Focus Areas
- 21 Portfolio Management Group Structure
- 27 Portfolio Management Resources
- 32 Portfolio Management Team Performance Ratings
- 34 Portfolio Management Team Focus
- 41 Portfolio Management Strategy
- 47 Analyzing the Current Portfolio
- 53 Adjusting the Portfolio to Match Goals
- 63 Lifecycle Management: Maximizing Portfolio Revenue
- 69 LCM Strategies and Tactics
- 97 Divestiture
Key Metrix
Chapter 1: Portfolio Management Group Structure, Resources and Focus Areas
Chapter Benefits
- Build a portfolio management group by exploring other companies'
approaches and resource benchmarks.
- Understand the team's role in aligning the portfolio with company goals -
and learn other functions' involvement, too.
- Examine portfolio management group performance ratings - discover
strengths and improvement areas in 9 key categories.
- Analyze group focus areas and prioritize team activities.
Chapter Data
- Portfolio management team budgets and staffing
- Portfolio management team alignment
- Prominence of dedicated portfolio management groups
- Number of brands supported by portfolio management teams
- Groups responsible for aligning brand and corporate strategy
- Portfolio management team influence on company decisions
- Percentage of portfolio management activities dedicated to outsourced
activities
- Portfolio management team performance ratings
- Challenges faced by portfolio management groups
- Percentage of time spent on products, by point in lifecycle
- Percentage of time spent on products, by brand revenue
- Effect of starting earlier on portfolio management activities
- Effect of increased spending on portfolio management activities
- Percentage of money spent on products, by brand revenue
Chapter 2: Portfolio Management Strategy
Chapter Benefits
- Follow a step-by-step guide to organizing your portfolio: Know which
questions to ask, develop criteria, prune wisely and involve the right people
at all stages of the process.
- Learn eight critical factors driving portfolio management strategy.
- Improve and accelerate portfolio decision making.
- Transition easily between clinical portfolio management strategy and
lifecycle management activities.
Chapter Data
- Groups involved in performing financial calculations for developmental
compounds
- Groups involved in evaluating in-licensing opportunities
- Groups involved in evaluating company acquisition targets
- Dealmaking problems experienced by development-oriented companies and
commercialization-oriented companies
- Final decision maker on lifecycle management tactics for developmental
compounds
Chapter 3: Lifecycle Management: Maximizing Portfolio Revenue
Chapter Benefits
- Increase revenues and extend market exclusivity.
- Discover which groups are involved in LCM activities and decision-making -
clearly map out who will do what and when.
- Peruse an overview of 13 LCM tactics and strategies.
- Weigh different factors for each strategy or tactic, such as time to plan,
cost and ROI, to develop a balanced LCM plan.
Chapter Data
- Top-performing strategies: dollars earned per $1 spent
- Prominence of dedicated lifecycle management teams
- Department to which lifecycle management teams report
- Groups that perform financial calculations and select LCM tactics for
launched compounds
- Final decision maker on lifecycle management tactics for launched compounds
- Average percentage of US and EU revenues lost in first year of generic
competition
- Significance of generics threats to LCM teams
- Average time spent implementing LCM strategy
- Additional dollars earned per dollar spent on
- New indications
- New formulations
- Next-generation products
- Additional dollars earned per dollar spent on combination products,
pediatric exclusivity, authorized generics, and disease management programs
- Percentage of companies using litigation, citizen petitions or pediatric
exclusivity
- When planning begins for the following:
- Pediatric exclusivity strategy
- Litigation strategy
- Pricing strategies
- Counter-promotion strategies
